In these waning days of the second decade of the twenty-first century, technologists and investors are beginning to lay the foundations for new, truly transformational technologies that have the potential to reshape entire industries and rewrite the rules of human understanding.
It may sound lofty, but new achievements from businesses and research institutions in areas like machine learning, quantum computing, and genetic engineering mean that the futures imagined in science fiction are simply becoming science.
And among the technologies that could potentially have the biggest effect on the way we live, nothing looms larger than genetic engineering.
Investors and entrepreneurs are deploying hundreds of millions of dollars to create the tools that researchers, scientists and industry will use to re-engineer the building blocks of life to perform different functions in agriculture, manufacturing and medicine.
One of these companies, 10X Genomics, which gives users hardware and software to determine the functionality of different genetic code, has already proven how lucrative this early market can be. The company, which had its initial public offering earlier this year is now worth $6 billion.
Another, the still-private company is Inscripta, helmed by a former TenX Genomics executive, the Boulder, Colo.-based startup is commercializing a machine that can let researchers design and manufacture small quantities of new organisms. If TenX Genomics is giving scientists and businesses a better way to read and understand the genome, then Inscripta is giving those same users a new way to write their own genetic code and make their own organisms.
It’s a technology that investors are falling over themselves to finance. The company, which closed on $105 million in financing earlier in the year (through several tranches which began in late 2018), has just raised another $125 million on the heels of launching its first commercial product. Investors in the round include new and previous investors like: Paladin Capital Group, JS Capital Management, Oak HC/FT and Venrock.
“Biology has unlimited potential to positively change this world,” says Kevin Ness, the chief executive of Inscripta. “It’s one of the most important new technology forces that will be a major player in the global economy.”
Ness sees Inscripta as breaking down one of the biggest barriers to the commercialization of genetic engineering, which is access to the technology.
While genome centers and biology foundries can manufacture massive quantities of new biological material for industrial uses, it’s too costly and centralized for most researchers. “We can put the biofoundry capabilities into a box that can be pushed to a global researcher,” says Ness.
Earlier this year the company announced that it was taking orders for its first bio-manufacturing product and the new capital is designed to pay for expanding its manufacturing capabilities.
That wasn’t the only barrier that Inscripta felt that it needed to breakdown. The company also developed a proprietary biochemistry for gene editing, hoping to avoid having to pay fees to one of the two laboratories that were engaged in a pitched legal battle over who owned the CRISPR technology (the Broad Institute and the University of California both had claims to the technology).